Issues related to the development of neurotoxin treatment for PTSD and other mental health related disorders in regards to veterans.
2026 · 3rd Quarter (July 1 - Sep 30)
OBJECT PHARMA
Filed by EAGLE POINT STRATEGIES LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Termination
- Posted
- Oct 15, 2026
- Income
- $10,000.00
- Expenses
- Not reported
- Registrant
- EAGLE POINT STRATEGIES LLC
- Client
- OBJECT PHARMA
- Filing UUID
- a95ff031-e593-42fd-836c-a5567de5d890
- Termination date
- Sep 30, 2026
Literal source text
Lobbying issues and bill citations
Issues related to the development of neurotoxin treatment for PTSD and other mental health related disorders in regards to veterans.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.